Back to top
more

Bristol Myers Squibb (BMY)

(Real Time Quote from BATS)

$41.85 USD

41.85
3,781,803

+0.37 (0.89%)

Updated Jun 14, 2024 11:58 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.08%
2Buy17.91%
3Hold9.44%
4Sell5.10%
5Strong Sell2.55%
S&P50011.04%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value B Growth F Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 34% (85 out of 249)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

New York-based Bristol-Myers Squibb is a one of the leading global specialty bio-pharmaceutical companies focused on the development of treatments targeting serious diseases. Backed by its blockbuster immune-oncology drug, Opdivo, Bristol-Myers has a strong oncology portfolio, consisting of other drugs like Revlimid, Sprycel, Yervoy and Empliciti. Beyond oncology, the company has important immunology and cardiovascular drugs like Orencia and Eliquis, which diversify its portfolio. Notably, in the cardiovascular space, Eliquis is now the global leading oral anti-coagulant drug. The company continues to experience growth in both the Eliquis brand and the market, while also advancing its Factor XIa inhibitor program..

Joseph Lu headshot

Can Carl Icahn Save Bristol Myers Squibb?

by Joseph Lu

Bristol-Myers Squibb Company (BMY) experienced slight growth after Carl Icahn, billionaire activist-investor, reportedly wants to take stake in the company.

    Arpita Dutt headshot

    Pharma Stock Roundup: Merck's Alzheimer's Study Halted, Allergan to Buy ZELTIQ

    by Arpita Dutt

    The main news this week was an update from Merck (MRK) regarding its Alzheimer's disease drug.

      Arpita Dutt headshot

      Pharma Stock Roundup: Allergan, GSK Top 4Q Earnings, Praluent Breather for Sanofi

      by Arpita Dutt

      Key highlights this week include earnings results from Allergan (AGN) and Glaxo, Sanofi's update regarding Praluent and Teva's ongoing woes.

        Gilead (GILD) Beats Q4 Earnings & Sales, View Disappoints

        by Zacks Equity Research

        Gilead Sciences' (GILD) fourth quarter results beat on both earnings and sales but the guidance for 2017 was quite disappointing.

          Sweta Killa headshot

          Q4 Earnings Faring Well for Pharma ETFs

          by Sweta Killa

          Despite the fact that the industry primes posted mixed results, the stocks witnessed smooth trading following their results.

            Portola, HealthCare Royalty Partners Ink $150 Million Deal

            by Zacks Equity Research

            Portola (PTLA) announced that it has signed a royalty agreement with HealthCare Royalty Partners (HCR) for $150 million.

              Bristol-Myers' Injectable Opdivo Gets FDA Approval for mUC

              by Zacks Equity Research

              Bristol-Myers Squibb Company (BMY) announced that the FDA has approved an injectable form of immuno-oncology drug Opdivo

                Arpita Dutt headshot

                Pharma Stock Roundup: Pfizer, Merck, LLY Report Results, Teva Hit by Copaxone Ruling

                by Arpita Dutt

                Key highlights this week include a court ruling in the Copaxone patent infringement lawsuit and earnings results from companies like Pfizer (PFE).

                  Roche (RHHBY) Beats on Earnings in 2016, Misses on Sales

                  by Zacks Equity Research

                  Roche beat on earnings but missed on sales in 2016 due to decline in sales of Lucentis, Pegasys, Avastin and Tarceva.

                    Implied Volatility Surging for Bristol-Myers Squibb Co. (BMY) Stock Options

                    by Zacks Equity Research

                    Bristol-Myers Squibb Co. (BMY) warrants investors' attention based on moves in the options market lately.

                      Drug Stocks Reporting Q4 Earnings on Jan 31: LLY and PFE

                      by Zacks Equity Research

                      Two pharma giants - Pfizer and Lilly - are set to report fourth-quarter results on Jan 31. Let's see how things are shaping up for this quarter.

                        Arpita Dutt headshot

                        Pharma Stock Roundup: J&J to Buy Actelion, Bristol-Myers' 4Q Results Disappoint

                        by Arpita Dutt

                        Key highlights this week include earnings reports from companies like Bristol-Myers (BMY) as well as the J&J-Actelion deal.

                          Bristol-Myers (BMY) Misses on Q4 Earnings, Beats on Sales

                          by Zacks Equity Research

                          Bristol-Myers (BMY) reported fourth quarter earnings of 63 cents on revenues of $5.23 billion.

                            Bristol-Myers (BMY) Q4 Earnings Miss Estimates

                            by Zacks Equity Research

                            Bristol-Myers (BMY) reported fourth quarter earnings of 63 cents on revenues of $5.23 billion.

                              Drug Stock Earnings to Watch on Jan 26: BIIB, CELG & BMY

                              by Zacks Equity Research

                              How will these three drug stocks, CELG, BMY and BIIB, which are all scheduled to report Q4 results on Jan 26, fare this earnings season?

                                Gilead (GILD) HCV Therapy Application Validated in Europe

                                by Zacks Equity Research

                                Gilead Sciences, Inc. (GILD) announced that its MAA for once-daily, single tablet regimen of Sovaldi, velpatasvir 100 mg and voxilaprevir 100 mg (SOF/VEL/VOX) for HCV treatment has been fully validated.

                                  Bristol-Myers Settles Litigation with Merck for Keytruda

                                  by Zacks Equity Research

                                  Bristol-Myers Squibb Company (BMY) along with partner Ono Pharmaceutical Company, Ltd. announced that both the companies have signed a global patent license agreement with Merck & Co., Inc. (MRK) to settle all litigation related to Keytruda.

                                    Sweta Killa headshot

                                    Can Q4 Earnings Revitalize Healthcare ETFs?

                                    by Sweta Killa

                                    The Q4 earnings could bring some near-term relief given that the sector is expected to post earnings growth of 2.9% and revenue growth of 5.6%.

                                      Bristol-Myers to Not Seek Accelerated Approval for Opdivo+Yervoy

                                      by Zacks Equity Research

                                      Bristol-Myers (BMY) won't seek an accelerated approval in the U.S. for the combination of its two immuno-oncology treatments Opdivo plus Yervoy for the first-line lung cancer.

                                        Bristol-Myers (BMY) Q4 Earnings: Will the Stock Disappoint?

                                        by Zacks Equity Research

                                        Bristol-Myers (BMY) is set to report fourth-quarter 2016 results on Jan 26. It reported a positive earnings surprise of 18.46% in the last quarter.

                                          AstraZeneca Offers Update on Immuno-Oncology Program

                                          by Zacks Equity Research

                                          AstraZeneca (AZN) provided an update on its late-stage immuno-oncology program for first-line NSCLC.

                                            ARIAD: Acquisition by Takeda Bodes Well, Competition a Risk

                                            by Zacks Equity Research

                                            On Jan 13, we issued an updated report on ARIAD Pharmaceuticals, Inc. (ARIA).

                                              Arpita Dutt headshot

                                              Pharma Stock Roundup: Trump Targets Pharma Again, Merck Up on Keytruda News

                                              by Arpita Dutt

                                              The sector was once again slammed by president-elect Donald Trump's comments this week regarding drug pricing.

                                                Sweta Killa headshot

                                                Trump Attacks Biotech & Pharma: ETFs Bleed

                                                by Sweta Killa

                                                Trump pledged to initiate a bidding process for drug cost that shed roughly $24.6 billion in 20 minutes from the nine biggest pharmaceutical companies by market cap.

                                                  Roche Gets Priority Review for Immunotherapy Drug Tecentriq

                                                  by Zacks Equity Research

                                                  Roche Holding AG's (RHHBY) Genentech announced that the FDA has accepted the company's supplemental Biologics License Application (sBLA) and granted Priority Review for cancer immunotherapy, Tecentriq.